389 related articles for article (PubMed ID: 27417897)
1. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.
MacEwan JP; Kamat SA; Duffy RA; Seabury S; Chou JW; Legacy SN; Hartry A; Eramo A; Karson C
Psychiatr Serv; 2016 Nov; 67(11):1183-1188. PubMed ID: 27417897
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
4. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
Lin CH; Chen FC; Chan HY; Hsu CC
Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
7. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
8. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
[TBL] [Abstract][Full Text] [Related]
9. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH
Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
[TBL] [Abstract][Full Text] [Related]
10. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
[TBL] [Abstract][Full Text] [Related]
11. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
Lin CH; Chen FC; Chan HY; Hsu CC
Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586
[TBL] [Abstract][Full Text] [Related]
13. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri TJ; Mican LM; Rozea H; Barner JC
Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
[TBL] [Abstract][Full Text] [Related]
14. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Curr Med Res Opin; 2018 Jan; 34(1):41-47. PubMed ID: 29057674
[TBL] [Abstract][Full Text] [Related]
15. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan.
Chen W; Wu CS; Liu CC; Kuo PH; Chan HY; Lin YH; Chung YE; Chen WJ
JAMA Netw Open; 2024 Jun; 7(6):e2417006. PubMed ID: 38884998
[TBL] [Abstract][Full Text] [Related]
16. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
17. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
[TBL] [Abstract][Full Text] [Related]
20. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
Lin CH; Chan HY; Hsu CC; Chen FC
J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
